Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility study

Απλή σελίδα τεκμηρίου
dc.contributor.authorFountzilas, G.en
dc.contributor.authorNicolaides, C.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorStathopoulos, G. P.en
dc.contributor.authorKontostolis, E.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorPavlidis, N.en
dc.date.accessioned2015-11-24T19:23:43Z
dc.date.available2015-11-24T19:23:43Z
dc.identifier.issn0030-2414-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22357
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntibiotics, Antineoplastic/*therapeutic useen
dc.subjectBreast Neoplasms/*drug therapy/*surgeryen
dc.subjectCombined Modality Therapyen
dc.subjectDose-Response Relationship, Drugen
dc.subjectDrug Administration Scheduleen
dc.subjectEpirubicin/*therapeutic useen
dc.subjectFeasibility Studiesen
dc.subjectFemaleen
dc.subjectFollow-Up Studiesen
dc.subjectGranulocyte Colony-Stimulating Factor/therapeutic useen
dc.subjectHumansen
dc.subjectLymphatic Metastasisen
dc.subjectMiddle Ageden
dc.titleDose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility studyen
heal.abstractForty-one patients with operable breast cancer and >/=10 positive axillary lymph nodes were treated with 6 cycles of dose-dense adjuvant chemotherapy consisting of epirubicin (100 mg/m2) every 2 weeks with G-CSF support. A total of 240 cycles were administered, all of them at full dose and 19 (8%) with a delay. Thirty-eight (93%) patients completed the treatment according to the protocol. The relative dose intensity of epirubicin was 0.99. Grade 3 toxicities included anemia (3%), nausea and vomiting (5%) and alopecia (71%). After a median follow-up of 40 months, 16 (39%) patients were free of relapse. In conclusion, the present study has shown that the administration of dose-dense chemotherapy with epirubicin is feasible in the adjuvant setting with minimal toxicity.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/9778614-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000011903-
heal.journalNameOncologyen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate1998-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ